MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 290 filers reported holding MIRATI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,650,088 | -2.8% | 184,060 | 0.0% | 0.13% | -16.0% |
| Q1 2023 | $6,843,351 | -10.7% | 184,060 | +8.9% | 0.16% | -12.4% |
| Q4 2022 | $7,660,109 | -31.0% | 169,060 | +6.3% | 0.18% | -39.2% |
| Q3 2022 | $11,109,000 | +4.0% | 159,060 | 0.0% | 0.29% | +13.6% |
| Q2 2022 | $10,678,000 | -15.2% | 159,060 | +3.9% | 0.26% | -5.5% |
| Q1 2022 | $12,585,000 | -4.7% | 153,060 | +70.1% | 0.27% | -4.2% |
| Q4 2021 | $13,202,000 | -11.4% | 90,000 | +6.9% | 0.28% | -17.4% |
| Q3 2021 | $14,899,000 | +31.3% | 84,220 | +19.9% | 0.34% | +31.7% |
| Q2 2021 | $11,349,000 | +37.0% | 70,260 | +45.3% | 0.26% | +15.4% |
| Q1 2021 | $8,284,000 | -8.5% | 48,360 | +17.4% | 0.23% | -25.3% |
| Q4 2020 | $9,051,000 | -6.8% | 41,210 | -29.6% | 0.30% | -21.0% |
| Q3 2020 | $9,714,000 | +45.4% | 58,500 | 0.0% | 0.38% | +40.0% |
| Q2 2020 | $6,679,000 | +240.8% | 58,500 | +129.4% | 0.28% | +167.0% |
| Q1 2020 | $1,960,000 | – | 25,500 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $136,602,679 | 87.83% |
| EcoR1 Capital, LLC | 5,748,399 | $250,400,260 | 8.45% |
| Boxer Capital, LLC | 3,201,440 | $139,454,726 | 7.42% |
| RTW INVESTMENTS, LP | 6,768,514 | $294,836,470 | 6.22% |
| Paradigm Biocapital Advisors LP | 1,668,116 | $72,663,133 | 4.93% |
| Avoro Capital Advisors LLC | 6,666,666 | $290,399,971 | 4.53% |
| Octagon Capital Advisors LP | 655,051 | $28,534,022 | 4.38% |
| Artal Group S.A. | 2,024,226 | $88,175 | 3.78% |
| Ally Bridge Group (NY) LLC | 70,283 | $3,061,527 | 3.59% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 216,000 | $9,404,640 | 3.17% |